Pulmonary Arterial Hypertension

Real-World Data of Combination Therapy With Macitentan to Treat PAH

November 27th 2020, 2:00pm

Combination therapy plays a central role in treating pulmonary arterial hypertension (PAH), and 2 abstracts presented at the CHEST annual meeting highlighted real-world treatment patterns.

Study of 2 Treatments for PAH Finds 1 Reduces Risk of Hospitalization

November 25th 2020, 1:00pm

Article

Compared with treprostinil, selexipag carried a 47% reduced risk of pulmonary arterial hypertension (PAH)-related hospitalization and 46% reduced risk of all-cause hospitalization.

Risk of Death Differs for Elderly Patients With PAH Taking Endothelin Receptor Antagonists

November 20th 2020, 2:30pm

Article

The mortality risk differs for the 3 endothelin receptor antagonists approved to treat pulmonary arterial hypertension (PAH) in elderly patients; however, a direct comparison in a controlled trial is still needed to confirm results.

Severe PAH Sharply Increases Maternal, Fetal Mortality in Pregnant Women

November 18th 2020, 6:18pm

Article

Severe pulmonary arterial hypertension (PAH) was associated with a significantly higher rate of maternal and fetal mortality.